Efficacy of i131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 5, 2004, Pages 1330-1336

  Zidan, Jamal ^a,b   Hefer, Elioz ^c   Iosilevski, Galina ^c   Drumea, Karen ^c   Stein, Moshe E ^c   Kuten, Abraham ^b,c   Israel, Ora ^b,c  

^a Rebecca Sieff Government Hospital   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Differentiated thyroid cancer; Optimal dose; Postoperative treatment

Indexed keywords

PATIENT MONITORING; SURGERY; TUMORS;

ABLATION RATES; OPTIMAL DOSES;

RADIOTHERAPY;

IODINE 131; THYROXINE; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; CONFIDENCE INTERVAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUBTOTAL THYROIDECTOMY; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; ARTICLE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PAPILLARY CARCINOMA; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; THYROID NEOPLASMS;

EID: 3242693585     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.036     Document Type: Article

References (43)

1. Mazzaferri E.L., Young R.L. Papillary thyroid carcinoma A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 70:1981;511-518
2. Sweeny D.C., Johnston G.S. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am. 24:1995;803-839
3. Mazzaferri E.L., Jhiang S.M. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97:1994;418-428
4. Fraker D.L., Skarulis M., Livolsi V. Thyroid tumors. Devita V.T., Rosenberg S.A., Hellman S. Cancer. Principles and practice of oncology. 5th ed:1997;1629-1652 Lippincott, New York
5. Ronga G., Fiorentino A., Paserio E., et al. Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med. 31:1990;1766-1771
6. Pineda J.D., Lee T., Ain K., et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 80:1995;1488-1492
7. Cady B., Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 104:1988;947-953
8. Samaan N.A., Maheshwari Y.K., Nader S., et al. Impact of therapy for differentiated carcinoma of the thyroid An analysis of 706 cases. J Clin Endocrinol Metab. 56:1983;1131-1138
9. Massin J.P., Savoie J.C., Garnier H., et al. Pulmonary metastases in differentiated thyroid carcinoma Study of 58 cases with implications for the primary tumor treatment. Cancer. 53:1984;982-992
10. Krishnamurthy G.T., Blahd W.H. Radioiodine I-131 therapy in the management of thyroid cancer A prospective study. Cancer. 40:1977;195-202
11. 131 for thyroid ablation. Ann Intern Med. 96:1982;51-53
12. Leung S.F., Law M.W., Ho S.K. Efficacy of low dose iodine-131 ablation of post-operative thyroid remnants A study of 69 cases. Br J Radiol. 65:1992;905-909
13. Creutzig H. High or low dose radioiodine ablation of thyroid remnants. Eur J Nucl Med. 12:1987;500-502
14. 131 therapy for well-differentiated thyroid cancer A quantitative radiation dosimetric approach - Outcome and validation in 85 patients. J Nucl Med. 33:1992;1132-1136
15. Becker D.V., Hurley J.R., Motazedi A., et al. Ablations of postsurgical thyroid remnants in patients with differentiated thyroid cancer can be achieved with less than whole body radiation. Proceedings of the 29th Annual Meeting of the Society of Nuclear Medicine, Miami Beach, FL, June 15-18. J Nucl Med. 23:1982;43
16. International Union Against Cancer (UICC). TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss; 1997. p. 47-50
17. Hurley J.R., Becker D.V. The use of radioiodine in the management of thyroid cancer. Freeman L.M., Weissmann H.S. Nuclear medicine annual. 1983;329-383 Raven Press, New York
18. Tsang R.W., Brierley J.D., Simpson W.J., et al. The effects of surgery, radioiodine, and external radiation on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 82:1998;375-388
19. Samuel A.M., Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer A quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med. 35:1994;1944-1950
20. 131 therapy in differentiated thyroid carcinoma MD Anderson Hospital experience. Cancer. 47:1981;664-671
21. Maxon H.R., Thomas S.R., Hertzberg V.S., et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 309:1983;937-941
22. 131 in 511 patients from 1947-1984 Experience at University of Michigan. J Nucl Med. 25:1984;1287-1293
23. Simpson W.J., Panzarella T., Carruthers J.S., et al. Papillary and follicular thyroid cancer, impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 14:1988;1063-1075
24. DeGroot L.J., Kaplan E.L., McCormick M., et al. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 71:1990;414-424
25. Samaan N.A., Schultz P.N., Hickey R.C., et al. The results of various modalities of treatment of well differentiated thyroid carcinomas A retrospective review of 1599 patients. J Clin Endocrinol Metab. 75:1992;714-720
26. Attie J.N., Bock G., Moskowitz G.W., et al. Postoperative radioactive iodine evaluation of total thyroidectomy for thyroid carcinoma Reappraisal and therapeutic implications. Head Neck. 14:1992;297-302
27. Emerick G.T., Duh Q.Y., Siperstein A.E., et al. Diagnosis, treatment and outcome of follicular thyroid carcinoma. Cancer. 72:1993;3287-3295
28. Farahati J., Reiners C., Stuschke M., et al. Differentiated thyroid cancer Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage-pT4). Cancer. 77:1996;172-180
29. 131 in the treatment of patients with differentiated thyroid cancer? Nucl Med Commun. 17:1996;199-207
30. 131. Int J Radiat Oncol Biol Phys. 36:1996;83-86
31. Vassilopoulou-Sellin R., Schultz P.N., Haynie T.P. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer. 78:1996;493-501
32. Lin W.Y., Shen Y.Y., Wang S.J. Short-term hazards of low-dose radioiodine ablation therapy in post surgical thyroid cancer patients. Clin Nucl Med. 21:1996;780-782
33. Loh K.C., Greenspan F.S., Gee L., et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas A retrospective analysis of 700 patients. J Clin Endocrinol Metab. 82:1997;3553-3562
34. Muratet J.P., Giraud P., Daver A., et al. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med. 38:1997;1362-1368
35. Thomas S.R., Maxon H.R., Kereiakes J.G. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 3:1976;253-255
36. McCowen K.D., Adler R.A., Ghaed N., et al. Low dose radioiodine thyroid ablation in post surgical patients with thyroid cancer. Am J Med. 61:1976;52-58
37. Ramacciotti C., Pretorius H.T., Line B.R., et al. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine Concise communication. J Nucl Med. 23:1982;483-489
38. Johansen K., Woodhouse N.J., Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine 131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med. 32:1991;252-254
39. 131 for remnant ablation in patients with differentiated thyroid carcinoma. Cancer. 77:1996;2574-2580
40. Hodgson D.C., Brierley J.D., Tsang R.W., et al. Prescribing 131 iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol. 47:1998;325-330
41. Waxman A., Ramanna L., Chapman N., et al. The significance of I-131 scan dose in patients with thyroid cancer Determination of ablation: Concise communication. J Nucl Med. 22:1981;861-865
42. Sabri O., Zimny M., Schreckenberger M., et al. Does thyroid stunning exists? A model with benign thyroid disease. Eur J Nucl Med. 27:2000;1591-1597
43. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice Management of thyroid carcinoma. Endocrin Pract. 7:2001;202-220